Advertisement

Amitriptyline and Depressions

  • Mellar P. DavisEmail author
Living reference work entry
  • 15 Downloads

Abstract

Amitriptyline was the second tricyclic antidepressant to be introduced into practice in the United States. In a network meta-analysis, amitriptyline is equivalent to selective serotonin reuptake inhibitors (SSRIs) and is superior to trazodone, fluoxetine, and reboxetine in efficacy. Dropouts for reasons of adverse effects were higher than for most antidepressants particularly in the outpatient setting. Therapeutic drug monitoring improves clinical utility since there are wide individual differences in serum drug levels per dose. Drug interactions are a result of competitive inhibition with the mixed function oxidases CYP2D6 and CYP2C19. Amitriptyline is effective in treating melancholic depression and psychotic depression if combined with an antipsychotic in the latter instance but increases the risk of mania in bipolar disorders. Amitriptyline adverse effects are largely related to antimuscarinic side effects. Overdoses are highly lethal due to arrhythmias.

References

  1. Achar E, Achar RA, Paiva TB, Campos AH, Schor N. Amitriptyline eliminates calculi through urinary tract smooth muscle relaxation. Kidney Int. 2003;64:1356–64.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev. 2018;4:CD008581.PubMedPubMedCentralGoogle Scholar
  3. Alcocer-Gomez E, De Miguel M, Casas-Barquero N, Nunez-Vasco J, Sanchez-Alcazar JA, Fernandez-Rodriguez A, Cordero MD. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun. 2014;36:111–7.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Alcocer-Gomez E, Casas-Barquero N, Williams MR, Romero-Guillena SL, Canadas-Lozano D, Bullon P, Sanchez-Alcazar JA, Navarro-Pando JM, Cordero MD. Antidepressants induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder. Pharmacol Res. 2017;121:114–21.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev. 2018;70:197–245.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Barbui C, Guaiana G, Hotopf M. Amitriptyline for inpatients and SSRIs for outpatients with depression? Systematic review and meta-regression analysis. Pharmacopsychiatry. 2004;37:93–7.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19:427–34.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Baumann P. New aspects in research on blood levels and bioavailability of antidepressants. Psychopathology. 1986;19(Suppl 2):79–84.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Baumann P, Jonzier-Perey M, Koeb L, Le PK, Tinguely D, Schopf J. Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline. Int Clin Psychopharmacol. 1986;1:89–101.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Berard A, Zhao JP, Sheehy O. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. BMJ Open. 2017;7:e013372.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, Mcquade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009;14:197–206.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Berry-Bibee EN, Kim MJ, Simmons KB, Tepper NK, Riley HE, Pagano HP, Curtis KM. Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review. Contraception. 2016;94:650–67.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Bighelli I, Castellazzi M, Cipriani A, Girlanda F, Guaiana G, Koesters M, Turrini G, Furukawa TA, Barbui C. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2018;4:CD010676.PubMedPubMedCentralGoogle Scholar
  14. Botney M, Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol. 1983;13:160–4.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:1321–5.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Bryant SG, Fisher S, Kluge RM. Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system. J Clin Psychopharmacol. 1987;7:78–82.CrossRefPubMedPubMedCentralGoogle Scholar
  17. Burch R. Antidepressants for preventive treatment of migraine. Curr Treat Options Neurol. 2019;21:18.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Chang M, Tybring G, Dahl ML, Lindh JD. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis. Clin Pharmacokinet. 2014;53:801–11.CrossRefPubMedPubMedCentralGoogle Scholar
  19. Chen LW, Chen MY, Lian ZP, Lin HS, Chien CC, Yin HL, Chu YH, Chen KY. Amitriptyline and sexual function: a systematic review updated for sexual health practice. Am J Mens Health. 2018;12:370–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Chen TY, Tzeng NS, Tai YM. Amitriptyline-induced acute kidney injury and acute hepatitis: a case report. Am J Ther. 2019;0:1–2.Google Scholar
  21. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–66.CrossRefPubMedPubMedCentralGoogle Scholar
  22. Coudore F, Fialip J, Eschalier A, Lavarenne J. Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice. Eur J Drug Metab Pharmacokinet. 1994;19:5–11.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Dandjinou M, Sheehy O, Berard A. Antidepressant use during pregnancy and the risk of gestational diabetes mellitus: a nested case-control study. BMJ Open. 2019;9:e025908.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Dean L. Amitriptyline therapy and CYP2D6 and CYP2C19 Genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Malheiro A, editors. Medical genetics summaries [Internet]. Bethesda: National Center for Biotechnology Information (US); 2017; 2012-.2017 Mar 23.Google Scholar
  25. Drugs for chronic insomnia. Med Lett Drugs Ther. 2018;60:201–205.Google Scholar
  26. Eshun-Wilson I, Siegfried N, Akena DH, Stein DJ, Obuku EA, Joska JA. Antidepressants for depression in adults with HIV infection. Cochrane Database Syst Rev. 2018;1:CD008525.PubMedPubMedCentralGoogle Scholar
  27. Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, Manson CC, Wilson S. Antidepressants for insomnia in adults. Cochrane Database Syst Rev. 2018;5:CD010753.PubMedPubMedCentralGoogle Scholar
  28. Franke L, Schewe HJ, Uebelhack R, Muller-Oerlinghausen B. Predictors of therapeutic effects in amitriptyline treatment – 1. Plasma drug levels. Pharmacopsychiatry. 2003;36:134–42.CrossRefPubMedPubMedCentralGoogle Scholar
  29. Furlanut M, Benetello P. The pharmacokinetics of tricyclic antidepressant drugs in the elderly. Pharmacol Res. 1990;22:15–25.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Furukawa T, McGuire H Barbui C. Low dosage tricyclic antidepressants for depression. Cochrane Database Syst Rev. 2003;(3):CD003197.Google Scholar
  31. Gassen NC, Hartmann J, Zschocke J, Stepan J, Hafner K, Zellner A, Kirmeier T, Kollmannsberger L, Wagner KV, Dedic N, Balsevich G, Deussing JM, Kloiber S, Lucae S, Holsboer F, Eder M, Uhr M, Ising M, Schmidt MV, Rein T. Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: evidence in cells, mice, and humans. PLoS Med. 2014;11:e1001755.CrossRefPubMedPubMedCentralGoogle Scholar
  32. Gassen NC, Hartmann J, Schmidt MV, Rein T. FKBP5/FKBP51 enhances autophagy to synergize with antidepressant action. Autophagy. 2015;11:578–80.CrossRefPubMedPubMedCentralGoogle Scholar
  33. Giros B, El Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, Caron MG. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol. 1992;42:383–90.PubMedPubMedCentralGoogle Scholar
  34. Gisev N, Nielsen S, Campbell G, Santo T, Mant A, Bruno R, Cohen M, Hall WD, Larance B, Lintzeris N, Farrell M, Degenhardt L. Antidepressant use among people prescribed opioids for chronic noncancer pain. Pain Med. 2019;20:2450–8.CrossRefPubMedPubMedCentralGoogle Scholar
  35. Gomolin IH, Melmed CA. Prolonged delirium without anticholinergic signs following amitriptyline overdose. Can Med Assoc J. 1983;129:1203–4.PubMedPubMedCentralGoogle Scholar
  36. Guaiana G, Barbui C, Hotopf M. Amitriptyline for depression. Cochrane Database Syst Rev. 2007;18:CD004186.Google Scholar
  37. Gulbins A, Grassme H, Hoehn R, Kohnen M, Edwards MJ, Kornhuber J, Gulbins E. Role of Janus-kinases in major depressive disorder. Neurosignals. 2016;24:71–80.CrossRefPubMedPubMedCentralGoogle Scholar
  38. Gupta SK, Shah JC, Hwang SS. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. Br J Clin Pharmacol. 1999;48:71–8.CrossRefPubMedPubMedCentralGoogle Scholar
  39. Haviv Y, Zini A, Sharav Y, Almoznino G, Benoliel R. Nortriptyline compared to amitriptyline for the treatment of persistent masticatory myofascial pain. J Oral Facial Pain Headache. 2019;33:7–13.CrossRefPubMedPubMedCentralGoogle Scholar
  40. Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev. 2013;CD002317.Google Scholar
  41. Hefner G, Hahn M, Hohner M, Roll SC, Klimke A, Hiemke C. QTc time correlates with amitriptyline and venlafaxine serum levels in elderly psychiatric inpatients. Pharmacopsychiatry. 2018;52:38–43.PubMedPubMedCentralGoogle Scholar
  42. Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Grunder G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mossner R, Muller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9–62.CrossRefPubMedPubMedCentralGoogle Scholar
  43. Jick H, et al. Adverse reactions to the tricyclic-antidepressant drugs. Report from Boston Collaborative Drug Surveillance Program. Lancet. 1972;1:529–31.Google Scholar
  44. Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008;22:1480–6.CrossRefPubMedPubMedCentralGoogle Scholar
  45. Kok RM, Vink D, Heeren TJ, Nolen WA. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. J Clin Psychiatry. 2007;68:1177–85.CrossRefPubMedPubMedCentralGoogle Scholar
  46. Kolla BP, Mansukhani MP, Bostwick JM. The influence of antidepressants on restless legs syndrome and periodic limb movements: a systematic review. Sleep Med Rev. 2018;38:131–40.CrossRefPubMedPubMedCentralGoogle Scholar
  47. Koszewska I, Rybakowski JK. Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology. 2009;59:12–6.CrossRefPubMedPubMedCentralGoogle Scholar
  48. Kozer E, Levichek Z, Hoshino N, Kapur B, Leombruno J, Taguchi N, Garcia-Bournissen F, Koren G, Ito S. The effect of amitriptyline, gabapentin, and carbamazepine on morphine-induced hypercarbia in rabbits. Anesth Analg. 2008;107:1216–22.CrossRefPubMedPubMedCentralGoogle Scholar
  49. Kumar Y, Kung S, Shinozaki G. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. J Psychopharmacol. 2014;28:1143–8.CrossRefPubMedPubMedCentralGoogle Scholar
  50. Kunzel HE, Ackl N, Hatzinger M, Held K, Holsboer-Trachsler E, Ising M, Kaschka W, Kasper S, Konstantinidis A, Sonntag A, Uhr M, Yassouridis A, Holsboer F, Steiger A. Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol – a double-blind multicenter trial. J Psychiatr Res. 2009;43:702–10.CrossRefPubMedPubMedCentralGoogle Scholar
  51. Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol. 1991;11:313–8.CrossRefPubMedPubMedCentralGoogle Scholar
  52. Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012;12:CD009138.PubMedPubMedCentralGoogle Scholar
  53. Lirk P, Haller I, Myers RR, Klimaschewski L, Kau YC, Hung YC, Gerner P. Mitigation of direct neurotoxic effects of lidocaine and amitriptyline by inhibition of p38 mitogen-activated protein kinase in vitro and in vivo. Anesthesiology. 2006;104:1266–73.CrossRefPubMedPubMedCentralGoogle Scholar
  54. Liu SJ, Wang RI. Increased sensitivity of the central nervous system to morphine analgesia by amitriptyline in naive and morphine-tolerant rats. Biochem Pharmacol. 1981;30:2103–9.CrossRefPubMedPubMedCentralGoogle Scholar
  55. Maarrawi J, Abdel Hay J, Kobaiter-Maarrawi S, Tabet P, Peyron R, Garcia-Larrea L. Randomized double-blind controlled study of bedtime low-dose amitriptyline in chronic neck pain. Eur J Pain. 2018;22:1180–7.CrossRefPubMedPubMedCentralGoogle Scholar
  56. Mestres J, Seifert SA, Oprea TI. Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther. 2011;90:662–5.CrossRefPubMedPubMedCentralGoogle Scholar
  57. Monteleone P, Fabrazzo M. Blood levels of mianserin and amitriptyline and clinical response in aged depressed patients. Pharmacopsychiatry. 1994;27:238–41.CrossRefPubMedPubMedCentralGoogle Scholar
  58. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev. 2006;25:CD003491.Google Scholar
  59. Muller-Siecheneder F, Muller MJ, Hillert A, Szegedi A, Wetzel H, Benkert O. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol. 1998;18:111–20.CrossRefPubMedPubMedCentralGoogle Scholar
  60. Nilges MR, Bondy ZB, Grace JA, Winsauer PJ. Opioid-enhancing antinociceptive effects of delta-9-tetrahydrocannabinol and amitriptyline in rhesus macaques. Exp Clin Psychopharmacol. 2019  https://doi.org/10.1037/pha0000313.
  61. Nishimura T, Maruguchi H, Nakao A, Nakayama S. Unusual complications from amitriptyline intoxication. BMJ Case Rep 2017;2017.  https://doi.org/10.1136/bcr-2017-219257.
  62. O’brien FE, Clarke G, Dinan TG, Cryan JF, Griffin BT. Human P-glycoprotein differentially affects antidepressant drug transport: relevance to blood-brain barrier permeability. Int J Neuropsychopharmacol. 2013;16:2259–72.CrossRefPubMedPubMedCentralGoogle Scholar
  63. Oskoui M, Pringsheim T, Billinghurst L, Potrebic S, Gersz EM, Gloss D, Holler-Managan Y, Leininger E, Licking N, Mack K, Powers SW, Sowell M, Cristina Victorio M, Yonker M, Zanitsch H, Hershey AD. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Headache. 2019;59:1144–57.CrossRefPubMedPubMedCentralGoogle Scholar
  64. Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018;4:CD011006.PubMedPubMedCentralGoogle Scholar
  65. Paksu S, Duran L, Altuntas M, Zengin H, Salis O, Ozsevik SN, Albayrak H, Murat N, Guzel A, Paksu MS. Amitriptyline overdose in emergency department of university hospital: evaluation of 250 patients. Hum Exp Toxicol. 2014;33:980–90.CrossRefPubMedPubMedCentralGoogle Scholar
  66. Palmer SC, Natale P, Ruospo M, Saglimbene VM, Rabindranath KS, Craig JC, Strippoli GF. Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis Cochrane Database Syst Rev. 2016;May 23;(5):CD004541.  https://doi.org/10.1002/14651858.CD004541.pub3.
  67. Park SH, Wackernah RC, Stimmel GL. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants? J Pharm Pract. 2014;27:71–8.CrossRefPubMedPubMedCentralGoogle Scholar
  68. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol. 1994;14:230–40.CrossRefPubMedPubMedCentralGoogle Scholar
  69. Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, Korbee LL, Porter LL, Hershey AD, Investigators C. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017;376:115–24.CrossRefPubMedPubMedCentralGoogle Scholar
  70. Preskorn SH, Mac DS. Plasma levels of amitriptyline: effect of age and sex. J Clin Psychiatry. 1985;46:276–7.PubMedPubMedCentralGoogle Scholar
  71. Pressman MD, Weiss LB. Experiences with Elavil: treatment of fifty-one cases of depression. Am J Psychiatry. 1961;118:74–5.CrossRefPubMedPubMedCentralGoogle Scholar
  72. Qureshi MH, Esper GJ, Bashir FF. When to consider prophylactic antimigraine therapy in children with migraine. Curr Treat Options Neurol. 2019;21:15.CrossRefPubMedPubMedCentralGoogle Scholar
  73. Rampello L, Alvano A, Chiechio S, Malaguarnera M, Raffaele R, Vecchio I, Nicoletti F. Evaluation of the prophylactic efficacy of amitriptyline and citalopram, alone or in combination, in patients with comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology. 2004;50:322–8.CrossRefPubMedPubMedCentralGoogle Scholar
  74. Rao ML, Deister A, Laux G, Staberock U, Hoflich G, Moller HJ. Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatry. 1996;29:97–102.CrossRefPubMedPubMedCentralGoogle Scholar
  75. Rayner L, Price A, Evans A, Valsraj K, Hotopf M, Higginson IJ. Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med. 2011;25:36–51.CrossRefPubMedPubMedCentralGoogle Scholar
  76. Rheker J, Winkler A, Doering BK, Rief W. Learning to experience side effects after antidepressant intake – results from a randomized, controlled, double-blind study. Psychopharmacology. 2017;234:329–38.CrossRefPubMedPubMedCentralGoogle Scholar
  77. Riblet N, Larson R, Watts BV, Holtzheimer P. Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2014;36:466–73.CrossRefPubMedPubMedCentralGoogle Scholar
  78. Richards BL, Whittle SL, Buchbinder R. Antidepressants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2011;Nov 9;(11):CD008920.  https://doi.org/10.1002/14651858.CD008920.pub2.
  79. Rocha FL, Fuzikawa C, Riera R, Hara C. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. J Clin Psychopharmacol. 2012;32:278–81.CrossRefPubMedPubMedCentralGoogle Scholar
  80. Rocha FL, Murad MG, Stumpf BP, Hara C, Fuzikawa C. Antidepressants for depression in Parkinson’s disease: systematic review and meta-analysis. J Psychopharmacol. 2013;27:417–23.CrossRefPubMedPubMedCentralGoogle Scholar
  81. Rodstein M, Oei LS. Cardiovascular side effects of long-term therapy with tricyclic antidepressants in the aged. J Am Geriatr Soc. 1979;27:231–4.CrossRefPubMedPubMedCentralGoogle Scholar
  82. Rosenblat JD, Kakar R, Mcintyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol. 2015;19. pii: pyv082.  https://doi.org/10.1136/10.1093/ijnp/pyv082
  83. Roy D, Dawling S. Application of an individually predicted dosage of amitriptyline to the treatment of depression. Int Clin Psychopharmacol. 1987;2:307–15.CrossRefPubMedPubMedCentralGoogle Scholar
  84. Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999;19:373–409.CrossRefPubMedPubMedCentralGoogle Scholar
  85. Sanna MD, Ghelardini C, Galeotti N. Effect of amitriptyline treatment on neurofilament-H protein in an experimental model of depression. Brain Res Bull. 2017;128:1–6.CrossRefPubMedPubMedCentralGoogle Scholar
  86. Schulz P, Dick P, Blaschke TF, Hollister L. Discrepancies between pharmacokinetic studies of amitriptyline. Clin Pharmacokinet. 1985;10:257–68.CrossRefPubMedPubMedCentralGoogle Scholar
  87. Sennef C, Timmer CJ, Sitsen JM. Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol. 2003;18:91–101.CrossRefPubMedPubMedCentralGoogle Scholar
  88. Solek P, Koszla O, Mytych J, Badura J, Chelminiak Z, Cuprys M, Fraczek J, Tabecka-Lonczynska A, Koziorowski M. Neuronal life or death linked to depression treatment: the interplay between drugs and their stress-related outcomes relate to single or combined drug therapies. Apoptosis. 2019;24:773–84.CrossRefPubMedPubMedCentralGoogle Scholar
  89. Stock EM, Zeber JE, Mcneal CJ, Banchs JE, Copeland LA. Psychotropic pharmacotherapy associated with QT prolongation among veterans with posttraumatic stress disorder. Ann Pharmacother. 2018;  https://doi.org/10.1177/1060028018769425.
  90. Tai YH, Tsai RY, Wang YH, Cherng CH, Tao PL, Liu TM, Wong CS. Amitriptyline induces nuclear transcription factor-kappaB-dependent glutamate transporter upregulation in chronic morphine-infused rats. Neuroscience. 2008;153:823–31.CrossRefPubMedPubMedCentralGoogle Scholar
  91. Takahashi H, Kamata M, Yoshida K, Higuchi H, Ishigooka J. Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series. Hum Psychopharmacol. 2008;23:217–20.CrossRefPubMedPubMedCentralGoogle Scholar
  92. Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, May J. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics. 2015;56:36–43.CrossRefPubMedPubMedCentralGoogle Scholar
  93. Uguz F. The use of antidepressant medications during pregnancy and the risk of neonatal seizures: a systematic review. J Clin Psychopharmacol. 2019;39:479–84.CrossRefPubMedPubMedCentralGoogle Scholar
  94. Ulrich S, Lauter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet. 2002;41:853–76.CrossRefPubMedPubMedCentralGoogle Scholar
  95. Unterecker S, Burger R, Hohage A, Deckert J, Pfuhlmann B. Interaction of valproic acid and amitriptyline: analysis of therapeutic drug monitoring data under naturalistic conditions. J Clin Psychopharmacol. 2013;33:561–4.CrossRefPubMedPubMedCentralGoogle Scholar
  96. Unterecker S, Pfuhlmann B, Kopf J, Kittel-Schneider S, Reif A, Deckert J. Increase of heart rate and QTc by amitriptyline, but not by venlafaxine, is correlated to serum concentration. J Clin Psychopharmacol. 2015;35:460–3.PubMedPubMedCentralGoogle Scholar
  97. Urquhart DM, Wluka AE, van Tulder M, Heritier S, Forbes A, Fong C, Wang Y, Sim MR, Gibson SJ, Arnold C, Cicuttini FM. Efficacy of low-dose amitriptyline for chronic low back pain: a randomized clinical trial. JAMA Intern Med. 2018;178:1474–81.CrossRefPubMedPubMedCentralGoogle Scholar
  98. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004;55:320–2.CrossRefPubMedPubMedCentralGoogle Scholar
  99. von Moltke LL, Greenblatt DJ, Shader RI. Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications. Clin Pharmacokinet. 1993;24:141–60.CrossRefGoogle Scholar
  100. Wijkstra J, Lijmer J, Burger H, Cipriani A, Geddes J, Nolen WA. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev. 2015;30:CD004044.Google Scholar
  101. Wright BM, Eiland EH 3rd, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy. 2013;33:344–59.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Palliative CareGeisinger Medical CenterDanvilleUSA

Section editors and affiliations

  • Gerd Laux
    • 1
  • Hans-Jürgen Möller
    • 2
  1. 1.Inst für Psychologische MedizinHaagGermany
  2. 2.Department of PsychiatryLudwig-Maximilians-University MunichMunichGermany

Personalised recommendations